CRISPR gene-editing controversy shows old ideas about East and West still prevail
By Calvin Wai-Loon Ho,
Econtimes
| 10. 24. 2016
The debate that followed initial experiments using the CRISPR-Cas9 genome editing tool show that old stereotypes about Asia still resonate in the West.
CRISPR-Cas9 is a gene editing tool that was first demonstrated US and Swedish labs in 2012. Basically, it uses segments of bacterial DNA that can make targeted cuts in a genome when paired with a specific guide protein (in this case, Cas9).
The technique is relatively uncomplicated compared with previous genome editing tools, which have been studied by scientists for more than 50 years. If applied to the genome of human germline cells, which pass on genetic material to produce human embryos, CRISPR-Cas9 has – at least in theory – the capability to alter humanity as we understand it.
Once certain genes are introduced or removed in germline cells (also known as gametes), the changes are passed onto the next generation. Given its potential to be misapplied towards eugenic ends and related ethical concerns, scientists generally agree that genetic modification of human gametes and embryos should not be done for reproductive purposes.
But it was less clear...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...